NASDAQ:HALO

Halozyme Therapeutics - HALO Stock Forecast, Price & News

$57.94

+0.09 (+0.16%)

(As of 12/9/2022 10:14 AM ET)

Add

Compare

Today's Range: $57.43
▼
$58.04
50-Day Range: $39.54
▼
$59.44
52-Week Range: $31.36
▼
$59.46

Volume: 12,809 shs
Average Volume: 1.31 million shs
Market Capitalization: $7.83 billion

P/E Ratio: 38.89
Dividend Yield: N/A
Price Target: $57.88

Halozyme Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 0.1% Downside
$57.88 Price Target
Short Interest: Healthy
7.57% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.12
Upright™ Environmental Score
News Sentiment: 0.12
Based on 16 Articles This Week
Insider Trading: Selling Shares
$2.48 M Sold Last Quarter
Proj. Earnings Growth: 41.95%
From $2.05 to $2.91 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.90 out of 5 stars

Medical Sector

40th out of 1,022 stocks

Biological Products, Except Diagnostic Industry

4th out of 171 stocks

2.5

Analyst's Opinion

Consensus Rating
Halozyme Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $57.88, Halozyme Therapeutics has a forecasted downside of 0.1% from its current price of $57.94.
Amount of Analyst Coverage
Halozyme Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
7.57% of the float of Halozyme Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Halozyme Therapeutics has a short interest ratio ("days to cover") of 8.7.
Change versus previous month
Short interest in Halozyme Therapeutics has recently decreased by 6.28%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Halozyme Therapeutics does not currently pay a dividend.
Dividend Growth
Halozyme Therapeutics does not have a long track record of dividend growth.

4.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Halozyme Therapeutics has received a 65.83% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Biopharmaceuticals" and "Medical technology engineering" products. See details.
Environmental Sustainability
The Environmental Impact score for Halozyme Therapeutics is -1.12.

2.8

News and Social Media Coverage

News Sentiment
Halozyme Therapeutics has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 16 news articles for Halozyme Therapeutics this week, compared to 2 articles on an average week.
Search Interest
24 people have searched for HALO on MarketBeat in the last 30 days. This is an increase of 60% compared to the previous 30 days.
MarketBeat Follows
8 people have added Halozyme Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Halozyme Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,477,250.00 in company stock.
Percentage Held by Insiders
Only 2.30% of the stock of Halozyme Therapeutics is held by insiders.
Percentage Held by Institutions
91.72% of the stock of Halozyme Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

4.4

Earnings and Valuation

Earnings Growth
Earnings for Halozyme Therapeutics are expected to grow by 41.95% in the coming year, from $2.05 to $2.91 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Halozyme Therapeutics is 38.89, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 120.67.
Price to Earnings Ratio vs. Sector
The P/E ratio of Halozyme Therapeutics is 38.89, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 93.10.
Price to Earnings Growth Ratio
Halozyme Therapeutics has a PEG Ratio of 0.91. PEG Ratios below 1 indicate that a company could be undervalued.
Price to Book Value per Share Ratio
Halozyme Therapeutics has a P/B Ratio of 41.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Halozyme Therapeutics (NASDAQ:HALO) Stock

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.

Receive HALO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Halozyme Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

HALO Stock News Headlines

December 9, 2022 | americanbankingnews.com

Halozyme Therapeutics (NASDAQ:HALO) Price Target Increased to $68.00 by Analysts at Benchmark

December 9, 2022 | americanbankingnews.com

Insider Selling: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Sells $557,400.00 in Stock

December 8, 2022 | markets.businessinsider.com

Where Halozyme Therapeutics Stands With Analysts

December 8, 2022 | finance.yahoo.com

Halozyme Therapeutics (HALO) Up 16.2% Since Last Earnings Report: Can It Continue?

December 8, 2022 | markets.businessinsider.com

5 Analysts Have This to Say About Halozyme Therapeutics

December 8, 2022 | americanbankingnews.com

Insider Selling: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Sells 10,000 Shares of Stock

December 7, 2022 | finance.yahoo.com

Estimating The Intrinsic Value Of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

December 3, 2022 | americanbankingnews.com

Halozyme Therapeutics (NASDAQ:HALO) Hits New 12-Month High at $57.68

December 3, 2022 | americanbankingnews.com

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives $55.38 Average Target Price from Brokerages

November 30, 2022 | finance.yahoo.com

LPCN: Focus on CNS Disorders

November 30, 2022 | americanbankingnews.com

Halozyme Therapeutics (NASDAQ:HALO) Now Covered by Wells Fargo & Company

November 27, 2022 | finance.yahoo.com

11 Best Diabetes Stocks To Buy Now

November 22, 2022 | markets.businessinsider.com

4 Analysts Have This to Say About Halozyme Therapeutics

November 15, 2022 | finance.yahoo.com

HALO Stock: Halozyme Gets Under Your Skin To Deliver Blockbuster Drugs And Booming Growth

November 15, 2022 | finance.yahoo.com

Should You Hold Halozyme Therapeutics (HALO)?

November 11, 2022 | finance.yahoo.com

Interview With Quoc Tran of Tran Capital

November 11, 2022 | realmoney.thestreet.com

Halozyme Therapeutics Earns a Second Price Target as Its Charts Improve

November 10, 2022 | nasdaq.com

HALO Crosses Above Average Analyst Target

November 10, 2022 | finance.yahoo.com

Halozyme Therapeutics Third Quarter 2022 Earnings: Beats Expectations

November 9, 2022 | finance.yahoo.com

The Blockbuster Potential That Sent IBD Stock Of The Day Halozyme Into A Breakout

November 8, 2022 | seekingalpha.com

Halozyme Therapeutics, Inc. (HALO) Q3 2022 Earnings Call Transcript

November 8, 2022 | finance.yahoo.com

HALOZYME REPORTS THIRD QUARTER 2022 FINANCIAL AND OPERATING RESULTS

November 7, 2022 | finance.yahoo.com

Should You Buy Halozyme Therapeutics (HALO) Ahead of Earnings?

October 25, 2022 | finance.yahoo.com

Halozyme to Report Third Quarter 2022 Financial and Operating Results

October 25, 2022 | finance.yahoo.com

Halozyme Therapeutics (HALO) Expected to Beat Earnings Estimates: Should You Buy?

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive HALO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Halozyme Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

HALO Company Calendar

Last Earnings: 11/02/2021
Today: 12/09/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 2/28/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:HALO
CUSIP: 40637H10
CIK: 1159036
Web: www.halozyme.com
Phone: 858-794-8889
Fax: 858-704-8311
Employees: 145
Year Founded: 1998

Price Target and Rating

Average Stock Price Forecast: $57.88
High Stock Price Forecast: $68.00
Low Stock Price Forecast: $42.00
Forecasted Upside/Downside: -0.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): $1.49
Trailing P/E Ratio: 38.89
Forward P/E Ratio: 28.26
P/E Growth: 0.91
Net Income: $402.71 million
Net Margins: 36.37%
Pretax Margin: 40.12%
Return on Equity: 134.71%
Return on Assets: 19.31%

Debt

Debt-to-Equity Ratio: 15.37
Current Ratio: 5.97
Quick Ratio: 5.03

Sales & Book Value

Annual Sales: $443.31 million
Price / Sales: 17.67
Cash Flow: $2.01 per share
Price / Cash Flow: 28.79
Book Value: $1.40 per share
Price / Book: 41.39

Miscellaneous

Outstanding Shares: 135,210,000
Free Float: 132,103,000
Market Cap: $7.83 billion
Optionable: Optionable
Beta: 1.26

Social Links

Key Executives

Dr. Helen I. Torley M.B. Ch. B. (Age 59)
M.R.C.P., Pres, CEO & Director
Comp: $1.65M

Dr. Michael J. LaBarre Ph.D. (Age 58)
Chief Technical Officer
Comp: $779.55k

Ms. Nicole LaBrosse (Age 39)
CFO & Director

Ms. Tram Bui
VP of Investor Relations & Corp. Communications

Mr. Mark Snyder Esq.
Gen. Counsel, Chief Compliance Officer & Corp. Sec.

Ms. Amy Marinne Fox
Chief HR Officer

Dr. Steve Knowles MBBS
Chief Medical Officer

Mr. Todd Butler
Chief of Staff to the CEO, VP & Head of Project Management

Dr. Christopher Bryant Ph.D. (Age 61)
Chief Manufacturing Officer & Head of Technical Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

HALO Stock - Frequently Asked Questions

Should I buy or sell Halozyme Therapeutics stock right now?: 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HALO shares.
View HALO analyst ratings or view top-rated stocks.
What is Halozyme Therapeutics' stock price forecast for 2023?: 7 Wall Street research analysts have issued 1-year price targets for Halozyme Therapeutics' stock. Their HALO share price forecasts range from $42.00 to $68.00. On average, they anticipate the company's stock price to reach $57.88 in the next year. This suggests a possible upside of 0.0% from the stock's current price.
View analysts price targets for HALO or view top-rated stocks among Wall Street analysts.
How have HALO shares performed in 2022?: Halozyme Therapeutics' stock was trading at $40.21 at the start of the year. Since then, HALO shares have increased by 43.9% and is now trading at $57.85.
View the best growth stocks for 2022 here.
When is Halozyme Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 28th 2023.
View our HALO earnings forecast.
How were Halozyme Therapeutics' earnings last quarter?: Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced its quarterly earnings results on Tuesday, November, 2nd. The biopharmaceutical company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.42 by $1.06. The biopharmaceutical company had revenue of $115.83 million for the quarter, compared to the consensus estimate of $101.94 million. Halozyme Therapeutics had a trailing twelve-month return on equity of 134.71% and a net margin of 36.37%. During the same period last year, the firm earned $0.25 EPS.
What guidance has Halozyme Therapeutics issued on next quarter's earnings?: Halozyme Therapeutics updated its FY 2022 earnings guidance on Thursday, December, 8th. The company provided earnings per share (EPS) guidance of $2.10-$2.25 for the period, compared to the consensus earnings per share estimate of $2.04. The company issued revenue guidance of $655.00 million-$685.00 million, compared to the consensus revenue estimate of $661.33 million.
What is Helen Torley's approval rating as Halozyme Therapeutics' CEO?: 12 employees have rated Halozyme Therapeutics Chief Executive Officer Helen Torley on Glassdoor.com. Helen Torley has an approval rating of 75% among the company's employees.

What other stocks do shareholders of Halozyme Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Halozyme Therapeutics investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Micron Technology (MU), Gilead Sciences (GILD), Athabasca Oil (ATH), NIC (EGOV), Allergan (AGN) and AbbVie (ABBV).
What is Halozyme Therapeutics' stock symbol?: Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO."
Who are Halozyme Therapeutics' major shareholders?: Halozyme Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.86%), Artisan Partners Limited Partnership (4.45%), Macquarie Group Ltd. (1.89%), Price T Rowe Associates Inc. MD (1.19%), Dimensional Fund Advisors LP (1.11%) and Eagle Asset Management Inc. (0.96%). Insiders that own company stock include Connie Matsui, Helen Torley, James M Daly, Jean-Pierre Bizzari, Jeffrey William Henderson, Kenneth J Kelley, Matthew L Posard, Michael J Labarre and Nicole Labrosse.
View institutional ownership trends.
How do I buy shares of Halozyme Therapeutics?: Shares of HALO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Halozyme Therapeutics' stock price today?: One share of HALO stock can currently be purchased for approximately $57.85.
How much money does Halozyme Therapeutics make?: Halozyme Therapeutics (NASDAQ:HALO) has a market capitalization of $7.82 billion and generates $443.31 million in revenue each year. The biopharmaceutical company earns $402.71 million in net income (profit) each year or $1.49 on an earnings per share basis.
How many employees does Halozyme Therapeutics have?: The company employs 145 workers across the globe.
Does Halozyme Therapeutics have any subsidiaries?: The following companies are subsidiares of Halozyme Therapeutics: Halozyme Holdings Ltd., Halozyme Inc., Halozyme Switzerland GmbH, and Halozyme Switzerland Holdings GmbH.
Read More
How can I contact Halozyme Therapeutics?: Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121-1345. The official website for the company is www.halozyme.com. The biopharmaceutical company can be reached via phone at 858-794-8889, via email at ir@halozyme.com, or via fax at 858-704-8311.

This page (NASDAQ:HALO) was last updated on 12/9/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial